

**Respiratory Syncytial Virus (RSV) A2 Phosphoprotein (P) Helper Plasmid, pA2-Popt**

**Catalog No. NR-36463**

**For research use only. Not for human use.**

**Contributor:**

BEI Resources

**Manufacturer:**

Martin L. Moore, Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA

**Product Description:**

NR-36463 is a component of a bacterial artificial chromosome (BAC)-based RSV rescue system that allows RSV infection to be monitored by fluorescence and is an important tool in RSV vaccine research and mutagenesis studies. Please refer to Appendix I for the manufacturer's RSV rescue protocol.

The P helper plasmid was constructed from codon-optimized RSV A2 P sequences. The codon-optimized cDNA sequences were synthesized and cloned into the pcDNA™3.1(+)<sup>+</sup> mammalian expression plasmid (Life Technologies™ Invitrogen™).<sup>1,2</sup> The plasmid was produced in *Escherichia coli*, strain 10-beta (a DH10B derivative, New England BioLabs®) and extracted using a Endo-Free Plasmid Maxi Kit (Qiagen).<sup>2</sup> The complete sequence for pA2-Popt is reported in Appendix II.

**Material Provided:**

Each vial contains 0.5 µg of plasmid DNA in RNase/DNase-free 10 mM Tris-HCl, 1 mM EDTA buffer (pH 8). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

**Packaging/Storage:**

NR-36463 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -80°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

**Functional Activity:**

Recombinant RSV was produced by co-transfection of BHK-21 clone BSR T7/5 cells<sup>3</sup> with pSynkRSV-I19F, a BAC plasmid containing RSV A2-line19F antigenomic DNA and the gene for the far-red fluorescent protein monomeric Katushka 2 (mKate2) to enable detection of infection through fluorescence, (NR-36460) and four helper plasmids encoding sequence-optimized genes from RSV strain A2: large polymerase (L) (NR-36461), nucleoprotein (N) (NR-36462), phosphoprotein (P) (NR-36463) and matrix 2-1 protein (M2-1) (NR-36464). RSV rescue and infection could be detected by red fluorescent syncytia.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Respiratory Syncytial Virus (RSV) A2 Phosphoprotein (P) Helper Plasmid, pA2-Popt, NR-36463."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmb15/index.htm](http://www.cdc.gov/biosafety/publications/bmb15/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

- Hotard, A. L., et al. "A Stabilized Respiratory Syncytial Virus Reverse Genetics System Amendable to Recombination-Mediated Mutagenesis." Virology 434 (2012): 129-136. PubMed: 23062737.

2. M. L. Moore, Personnel Communication.
3. Buchholz, U. J., S. Finke and K. -K. Conzelmann. "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and Human RSV Leader Region Acts as a Functional BRSV Genome Promoter." J. Virol. 73 (1999): 251-259. PubMed: 9847328.

ATCC® is a trademark of the American Type Culture Collection.



Appendix I

**Transfection Procedure for Virus Recovery of Recombinant Respiratory Syncytial Virus**

**Materials (Suggested suppliers and catalog numbers are indicated):**

BHK-21 clone BSR T7/5 cell cultures or alternative cells [BHK21 cells (ATCC® CCL10™) transfected with phage T7 polymerase from Modified Vaccinia Ankara (MVA)] **Note:** This protocol is optimized for use with BHK-21 clone BSR T7/5 cells. Use of alternative cells may result in decreased recovery of RSV.

Opti-MEM (serum-free) (Gibco/Life Technologies catalog #11058-021)

GMEM [Glasgow's MEM (Gibco/Life Technologies catalog #11710-035)] + 3% FBS

MEM non-essential amino acids (NEAA) 100X solution (Gibco/Life Technologies catalog #11140-050)

G418 sulfate, 50 mg/mL solution (500X) (Agilent Technologies Genomics catalog # 200049)

Trypsin-EDTA (0.25%) (Gibco/Life Technologies catalog #25200-072)

Antibiotic-Antimycotic solution, penicillin/streptomycin/amphotericin (100X) (Corning cellgro® catalog #30-004-CI) or equivalent

Plasmid with RSV antigenome (NR-36460) each vial contains 0.5 µg in 5 µL total volume **Note:** This protocol requires 0.8 µg of pSynkRSV-I19F; thus 2 vials of NR-36460 are required per transfection.)

Helper Plasmids – (all codon optimized) each vial contains 0.5 µg in 5 µL total volume:

pA2-Lopt, L protein (NR-36461)

pA2-Nopt, N protein (NR-36462)

pA2-Popt, P protein (NR-36463)

pA2-M2-1opt, M2-1 protein (NR-36464)

Lipofectamine 2000 transfection reagent (Gibco/Life Technologies catalog #11668-019)

Phosphate buffered saline pH 7.2 (Gibco/Life Technologies catalog #20012027)

6-well tissue culture plates

25 cm<sup>2</sup> tissue culture flasks

Shaker/rocker plate

Tissue culture humidified incubator with 3% to 5% CO<sub>2</sub>

Assorted sterile pipettes and tips

**Procedure:**

**Note:** This protocol assumes the user is familiar with cell culture techniques and transfection procedures.

1. Initial cell culture:
  - a. For routine sub-passage of BSR T7/5 cells, prepare new 25 cm<sup>2</sup> cultures at a ratio of one donor culture to three new cultures, based on surface area of the culture flasks (1:3 passage ratio). Use GMEM with 3% FBS + 1X NEAA + 1X antibiotics as growth medium, 5 mL per flask. When maintaining donor cultures, add 1X G418 to the growth medium every other passage.
  - b. For transfections, sub-pass BSR T7/5 cells from “donor” cultures into 6 well plates so they will be 100% confluent at time of transfection. Use one 25 cm<sup>2</sup> culture to prepare one 6 well plate (1:2.5 passage ratio).
2. Prepare 6 well plates for transfection from 25 cm<sup>2</sup> donor cultures. Determine how many plates will be required and use the corresponding number of flasks. Aspirate the growth medium from the flasks, and then add 0.25 mL of warm trypsin-EDTA per 25 cm<sup>2</sup> flask. Rock flasks to distribute the trypsin-EDTA and incubate at 37°C for 5 to 10 minutes. When cells start to dislodge from the flask, add 12 mL of GMEM with 3% FBS to each flask and use a pipet to suspend the cells in this growth medium. Add 2 mL of the cell suspension to each well in the 6 well plates. Incubate the plates at 37°C in the tissue culture incubator until the cell sheets are confluent and ready for transfection.
3. Prepare the reagents for the transfection procedure. Transfection will be done using Lipofectamine 2000 as the transfection reagent. Additionally, it is important to include control transfections (Lipofectamine only/wild type virus for mutants etc.)
  - a. Use a 3:1 ratio of Lipofectamine (µL) to plasmid/helper plasmid (µg). Dilute each component with Opti-MEM to make 100 µL of each. After dilution, allow each dilution to sit at room temperature for 5 minutes.
  - b. Use the following amounts of each component per transfection:
 

i. RSV antigenome (NR-36460)	0.8 µg (8 µL of 0.1 µg/µL ) + 92 µL Opti-MEM
<b>(2 vials of NR-36460 are required per transfection.)</b>	
ii. pA2-Lopt, L protein (NR-36461)	0.2 µg (2 µL of 0.1 µg/µL) + 98 µL Opti-MEM
iii. pA2-Nopt, N protein (NR-36462)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM
iv. pA2-Popt, P protein (NR-36463)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM
v. pA2-M2-1opt, M2-1 protein (NR-36464)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM

vi. Lipofectamine 2000

6.6  $\mu$ L + 93.4  $\mu$ L Opti-MEM

Note: For multiple transfections increase the above quantities proportionally.

- c. After allowing the diluted components to sit at room temperature for 5 minutes, combine all six components in one vial, mix gently and incubate the transfection mixture at room temperature for 20 minutes.
  - d. Transfection mixtures should be 600  $\mu$ L total (Opti-MEM, Lipofectin, and DNA)
  - e. Aspirate the media from the BSR T7/5 cell culture plate, wash cells twice with 1 mL warm Opti-MEM for each wash, and aspirate the final wash.
  - f. Add 600  $\mu$ L transfection mixture to each well and incubate the plate 2 hours at room temperature on a shaker/rocker plate set at low speed.
  - g. After 2 hours, add an additional 600  $\mu$ L warm Opti-MEM per well and place plate in a 37°C tissue culture incubator overnight (8-12 hours).
4. After incubation, aspirate and discard the transfection mixture from the wells, wash each well once with 1 mL warm sterile PBS, aspirate the PBS and replace with 2 mL of warm GMEM with 3% FBS per well. Continue incubating at 37°C in the tissue culture incubator overnight.
  5. Day 2 post transfection, sub-pass the cells into 25 cm<sup>2</sup> flasks using the trypsin-EDTA procedure described above. Pass at a 1:3 surface area ratio unless cell morphology appears weak, in which case the ratio should be decreased accordingly up to an even 1:1 ratio. (Note: surface area of each well in the 6 well plate is 10 cm<sup>2</sup>). Cells should remain in GMEM with 3% FBS throughout the rest of recovery.
  6. Monitor flasks for cytopathic effect (CPE) and sub-pass at 1:3 ratio into new 25 cm<sup>2</sup> flasks as needed (approximately every 48 hours). CPE shows first as mini-syncytia and then grows into rounded up clumps of cells.
  7. When CPE is evident throughout the flask, scrape the cells into the growth media and aliquot into cryovials. Freeze at -80°C or colder.

Appendix 2: pA2-Popt Sequence

1 GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACCTCTCAGTACAATCTGCTCTGATG 60  
 CTGCCTAGCCCTCTAGAGGGGCTAGGGGATACCACGTGAGAGTCATGTTAGACGAGACTAC

61 CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG 120  
 GCGGTATCAATTCCGGTCATAGACGAGGGACGAACACACAACCTCCAGCGACTCATCACGC

121 CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGC 180  
 GCTCGTTTTAAATTCGATGTTGTTCCGTTCCGAACCTGGCTGTTAACGTACTTCTTAGACG

181 TTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT 240  
 AATCCCAATCCGCAAAACGCGACGAAGCGCTACATGCCCGGTCTATATGCGCAACTGTAA

241 GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATA 300  
 CTAATAACTGATCAATAATTATCATTAGTTAATGCCCCAGTAATCAAGTATCGGGTATAT

301 TGGAGTTCGCGGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC 360  
 ACCTCAAGGCGCAATGTATTGAATGCCATTTACGGGGCGGACCGACTGGCGGGTTGCTGG

361 CCCGCCCATGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC 420  
 GGGCGGGTAACTGCAGTTATTACTGCATACAAGGGTATCATTGCGGTTATCCCTGAAAGG

421 ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT 480  
 TAACTGCAGTTACCCACCTCATAAATGCCATTTGACGGGTGAACCGTCATGTAGTTCACA

481 ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT 540  
 TAGTATACGGTTCATGCGGGGATAACTGCAGTTACTGCCATTTACGGGGCGGACCGTAA

541 ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA 600  
 TACGGGTTCATGTACTGGAATACCCTGAAAGGATGAACCGTCATGTAGATGCATAATCAGT

601 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG 660  
 AGCGATAATGGTACCCTACGCCAAAACCGTCATGTAGTTACCCGCACCTATCGCCAAAC

661 ACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTTGGCACC 720  
 TGAGTGCCCTAAAGGTTTCAGAGGTGGGGTAACTGCAGTTACCCTCAAACAAAACCGTGG

721 AAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCG 780  
 TTTTAGTTGCCCTGAAAGGTTTTACAGCATTGTTGAGGCGGGGTAACCTGCGTTTACCCGC

781 GTAGGCGTGACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA 840  
 CATCCGCACATGCCACCCTCCAGATATATTCGTCTCGAGAGACCGATTGATCTCTTGGGT  
 T7 promoter (863,881)  
 |

841 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGC 900  
 GACGAATGACCGAATAGCTTTAATTATGCTGAGTGATATCCCTCTGGGTTTCGACCGATCG  
 KpnI RSV phosphoprotein (929,1654)  
 | |

901 GTTTAAACTTAAGCTTGGTACCGCCACCATGGAAAAGTTCGCCCCGAGTTCACGGCGA 960  
 CAAATTTGAATTCGAACCATGGCGGTGGTACCTTTTCAAGCGGGGGCTCAAGGTGCCGCT

961 GGACGCCAACAAACCGGGCCACCAAGTTTCTGGAATCCATCAAGGGCAAGTTCACCAGCCC 1020  
 CCTGCGGTTGTTGGCCCCGGTGGTTCAAAGACCTTAGGTAGTTCCCGTTCAAGTGGTCGGG

1021 CAAGGACCCCAAGAAGAAGGACAGCATCATCAGCGTGAACAGCATCGACATCGAAGTGAC 1080  
 GTTCTGCGGTTCTTCTTCTCCTGTGCTAGTAGTCGCACTTGTCTGCTAGCTGTAGCTTCACTG

1081 CAAAGAGAGCCCCATCACCAGCAACAGCACCATCATCAACCCACCAACGAGACAGACGA 1140  
 GTTTCTCTCGGGGTAGTGGTCGTTGTCTGCTGTTAGTTGGGGTGGTTGCTCTGTCTGCT

1141 CACCGCCGGCAACAAGCCCAACTACCAGCGGAAGCCCCTGGTGTCCCTTCAAAGAGGACCC 1200  
 GTGGCGGCCGTTGTTTCGGGTTGATGGTCGCCTTCGGGGACCACAGGAAGTTTCTCCTGGG

1201 CACCCCCAGCGACAACCCCTTACAGCAAGCTGTACAAAGAGACAATCGAGACATTTCGACAA 1260  
 GTGGGGTTCGCTGTTGGGGAAGTCGTTTCGACATGTTTCTCTGTTAGCTCTGTAAGCTGTT

1261 CAACGAGGAAGAGAGCAGCTACAGCTACGAGGAAATCAACGACCAGACCAACGACAACAT 1320  
 GTTGCTCCTTCTCTCGTCGATGTGCGATGCTCCTTTAGTTGCTGGTCTGGTTGCTGTTGTA

1321 CACCGCCAGACTGGACCGGATCGACGAGAAGCTGAGCGAGATCCTGGGCATGCTGCACAC 1380  
 GTGGCGGTCTGACCTGGCCTAGCTGCTCTTCGACTCGCTCTAGGACCCGTACGACGTGTG

1381 CCTGGTGGTGGCCTCTGCCGGCCCTACAAGCGCCAGAGATGGCATCCGGGACGCCATGAT 1440  
 GGACCACCACCGGAGACGGCCGGGATGTTTCGCGGTCTCTACCGTAGGCCCTGCGGTA

1441 CGGCCTGCGGGAAGAGATGATCGAGAAGATCCGGACCGAGGCCCTGATGACCAACGACCG 1500  
 GCCCGACGCCCTTCTCTACTAGCTCTTCTAGGCCTGGCTCCGGGACTACTGGTTGCTGGC

1501 GCTGGAAGCCATGGCCCCGGCTGCGGAACGAGGAATCCGAGAAGATGGCCAAGGACACCAG 1560  
 CGACCTTCGGTACCGGGCCGACGCCTTGCTCCTTAGGCTCTTCTACCGGTTCTGTGGTC

1561 CGACGAGGTGTCCCTGAACCCACCTCTGAGAAGCTGAACAACCTGCTGGAAGGCAACGA 1620  
 GCTGCTCCACAGGGACTTGGGGTGGAGACTCTTCGACTTGTGGACGACCTTCCGTTGCT

XhoI  
|

1621 CAGCGACAACGACCTGAGCCTGGAAGATTTCTGACTCGAGTCTAGAGGGCCCGTTTAAAC 1680  
 GTCGCTGTTGCTGGACTCGGACCTTCTAAAGACTGAGCTCAGATCTCCGGGCAAATTTG

1681 CCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCTCCCC 1740  
 GGCGACTAGTCGGAGCTGACACGGAAGATCAACGGTCGGTAGACAACAACGGGGAGGGG

1741 CGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCCTGTCCTTTCTAATAAAAATGAGGA 1800  
 GCACGGAAGGAAGTGGGACCTTCCACGGTGAGGGTGACAGGAAAGGATTATTTTACTCCT

1801 AATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGA 1860  
 TTAACGTAGCGTAACAGACTCATCCACAGTAAGATAAGACCCCCACCCACCCCGTCT

1861 CAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTAT 1920  
 GTCGTTCCCCCTCCTAACCTTCTGTTATCGTCCGTACGACCCTACGCCACCCGAGATA

1921 GGCTTCTGAGGCGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAG 1980  
 CCGAAGACTCCGCCTTCTTGGTTCGACCCCGAGATCCCCCATAGGGGTGCGCGGGACATC

f1 origin (1985,2291)

1981 CGGCGCATTAAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAG 2040  
 GCCGCGTAATTCGCGCCGCCACACCACCAATGCGCGTCGCACTGGCGATGTGAACGGTC

2041 CGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTTCGCCGGCTT 2100  
 GCGGGATCGCGGGCGAGGAAAGCGAAAGAAGGGAAGGAAAGAGCGGTGCAAGCGGCCGAA

2101 TCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCA 2160  
 AGGGGCAGTTCGAGATTTAGCCCCGAGGGAAATCCCAAGGCTAAATCACGAAATGCCGT

2161 CCTCGACCCCAAAAACTTGATTAGGGTGTGGTTCACGTAGTGGGCCATCGCCCTGATA 2220  
 GGAGCTGGGGTTTTTTGAACTAATCCCACTACCAAGTGCATCACCCGGTAGCGGGACTAT

2221 GACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCA 2280  
 CTGCCAAAAAGCGGGAAACTGCAACCTCAGGTGCAAGAAATTATCACCTGAGAACAAGGT

2281 AACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCC 2340  
 TTGACCTTGTGTGAGTTGGGATAGAGCCAGATAAGAAAATAAATATTCCTAAAACGG

2341 GATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATT 2400  
 CTAAAGCCGGATAACCAATTTTTTACTCGACTAAATTTGTTTTTAAATTTGCGCTTAATTA  
 SV40 promoter (2423,2744)

2401 CTGTGGAATGTGTGTCAGTTAGGGTGTGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGT 2460  
 GACACCTTACACACAGTCAATCCCACACCTTTCAGGGTCCGAGGGTTCGTCCGTCTTCA

2461 ATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCA 2520  
 TACGTTTCGTACGTAGAGTTAATCAGTCGTTGGTCCACACCTTTCAGGGTCCGAGGGT

2521 GCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTA 2580  
 CGTCCGTCTTCATACGTTTCGTACGTAGAGTTAATCAGTCGTTGGTATCAGGGCGGGGAT  
 SV40 origin (2590,2667)

2581 ACTCCGCCCATCCCGCCCCTAACTCCGCCAGTTCCGCCATTCTCCGCCCATGGCTGA 2640  
 TGAGGCGGGTAGGGCGGGGATTGAGGCGGGTCAAGGCGGGTAAGAGGCGGGGTACCGACT

2641 CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCCTCTGCCTCTGAGCTATTCCAGAAG 2700  
 GATTAATAAATAAATACGTCTCCGGCTCCGGCGGAGACGGAGACTCGATAAGGTCTTC

2701 TAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATA 2760  
 ATCACTCTCCGAAAAACCTCCGGATCCGAAAACGTTTTTCGAGGGCCCTCGAACATAT  
 neomycin<sup>R</sup> (2806,3600)

2761 TCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGAT 2820  
 AGGTAAAAGCCTAGACTAGTTCTCTGTCTACTCTAGCAAAGCGTACTAACTTGTCTA

2821 GGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTTCGGCTATGACTGGGCA 2880  
 CCTAACGTGCGTCCAAGAGGCCGGCGAACCCACCTCTCCGATAAGCCGATACTGACCCGT

2881 CAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCG 2940  
 GTTGTCTGTTAGCCGACGAGACTACGGCGGCACAAGGCCGACAGTCGCGTCCCCGCGGGC



2941 GTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCG 3000  
 CAAGAAAAACAGTTCTGGCTGGACAGGCCACGGGACTTACTTGACGTCCTGCTCCGTCGC

3001 CGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACT 3060  
 GCCGATAGCACCGACCGGTGCTGCCCCGAAGGAACGCGTCGACACGAGCTGCAACAGTGA

3061 GAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCACT 3120  
 CTTCCGCCCTTCCCTGACCGACGATAAACCCTTACGGCCCCGTCTAGAGGACAGTAGA

3121 CACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACG 3180  
 GTGGAACGAGGACGGCTCTTTCATAGGTAGTACCGACTACGTTACGCCGCCGACGTATGC

3181 CTTGATCCGGCTACCTGCCATTTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGT 3240  
 GAACTAGGCCGATGGACGGGTAAGCTGGTGGTTCGCTTTGTAGCGTAGCTCGCTCGTGCA

3241 ACTCGGATGGAAGCCGGTCTTGTGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTC 3300  
 TGAGCCTACCTTCGGCCAGAACAGCTAGTCCCTACTAGACCTGCTTCTCGTAGTCCCCGAG

3301 GCGCCAGCCGAAGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTC 3360  
 CGCGGTTCGGCTTGACAAGCGGTCCGAGTTCGCGCGTACGGGCTGCCGCTCCTAGAGCAG

3361 GTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGA 3420  
 CACTGGGTACCGCTACGGACGAACGGCTTATAGTACCACCTTTTACCGGCGAAAAGACCT

3421 TTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACC 3480  
 AAGTAGCTGACACCGGCCGACCCACACCCGCTGGCGATAGTCCCTGTATCGCAACCGATGG

3481 CGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCCTCGTGCTTTACGGT 3540  
 GCACTATAACGACTTCTCGAACCGCCGCTTACCCGACTGGCGAAGGAGCACGAAATGCCA

3541 ATCGCCGCTCCCGATTTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGA 3600  
 TAGCGGCGAGGGCTAAGCGTCGCGTAGCGGAAGATAGCGGAAGAACTGCTCAAGAAGACT

3601 GCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCAACCTGCCATCACGAGATT 3660  
 CGCCCTGAGACCCCAAGCTTTACTGGCTGGTTCGCTGCGGGTTGGACGGTAGTGCTCTAA

3661 TCGATTCCACCGCCGCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCG 3720  
 AGCTAAGGTGGCGGCGGAAGATACTTTCCAACCCGAAGCCTTAGCAAAAGGCCCTGCGGC

3721 GCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCACCCCAACTTGT 3780  
 CGACCTACTAGGAGGTGCGCCCCCTAGAGTACGACCTCAAGAAGCGGGTGGGGTTGAACA

3781 TTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAG 3840  
 AATAACGTGAATATTACCAATGTTTATTTTCGTTATCGTAGTGTTTAAAGTGTTTATTTT

3841 CATTTTTTTCACTGCATTCTAGTTGTGGTTTTGTCCAACTCATCAATGTATCTTATCATG 3900  
 GTAAAAAAGTGACGTAAGATCAACACCAACAGGTTTGAGTAGTTACATAGAATAGTAC

3901 TCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCCTG 3960  
 AGACATATGGCAGCTGGAGATCGATCTCGAACCCGATTAGTACCAGTATCGACAAAGGAC  
 lac promoter (3993,4022)

3961 TGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTA 4020  
 AACTTTAACAATAGGCGAGTGTTAAGGTGTGTTGTATGCTCGGCCTTCGTATTTACAT



4021 AAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCG 4080  
TTCGGACCCACGATTACTCACTCGATTGAGTGTAATTAACGCAACGCGAGTGACGGGG

4081 CTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGGGGA 4140  
GAAAGGTCAGCCCTTTGGACAGCACGGTCGACGTAATTACTTAGCCGGTTGCGCGCCCT

4141 GAGGCGGTTTTCGTATTGGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGG 4200  
CTCCGCCAAACGCATAACCCGCGAGAAGGCGAAGGAGCGAGTGACTGAGCGACGCGAGCC

4201 TCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAG 4260  
AGCAAGCCGACGCCGCTCGCCATAGTCGAGTGAGTTTCCGCCATTATGCCAATAGGTGTC

4261 AATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACC 4320  
TTAGTCCCCTATTGCGTCCTTTCTTGTACTCTCGTTTCCGGTCGTTTCCGGTCCTTG  
pBR322 origin (4331,4947)  
|

4321 GTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACA 4380  
CATTTTTCCGGCGCAACGACCGCAAAAAGGTATCCGAGGCGGGGGGACTGCTCGTAGTGT

4381 AAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAACCAGGCGT 4440  
TTTTAGCTGCGAGTTCAGTCTCCACCGCTTTGGGCTGTCCTGATATTTCTATGGTCCGCA

4441 TTCCCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC 4500  
AAGGGGACCTTCGAGGGAGCACGCGAGAGGACAAGGCTGGGACGGCGAATGGCCTATGG

4501 TGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATC 4560  
ACAGGCGAAAGAGGGAAGCCCTTCGCACCGCGAAAGAGTATCGAGTGCGACATCCATAG

4561 TCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTTCCAGC 4620  
AGTCAAGCCACATCCAGCAAGCGAGGTTGACCCGACACACGTGCTTGGGGGGCAAGTCG

4621 CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGTAAGACACGACT 4680  
GGCTGGCGACGCGGAATAGGCCATTGATAGCAGAACTCAGGTTGGGCCATTCTGTGCTGA

4681 TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG 4740  
ATAGCGGTGACCGTCGTGGTGACCATTTGTCCTAATCGTCTCGCTCCATACATCCGCCAC

4741 CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTA 4800  
GATGTCTCAAGAACTTACCACCGGATTGATGCCGATGTGATCTTCTTGTCAAAACCAT

4801 TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCA 4860  
AGACGCGAGACGACTTCGGTCAATGGAAGCCTTTTTTCTCAACCATCGAGAACTAGGCCGT

4861 AACAAACCACCGCTGGTAGCGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAA 4920  
TTGTTTGGTGGCGACCATCGCCAAAAAACAAACGTTGTCGTCTAATGCGCGTCTTTTT

4921 AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGTCTGACGCTCAGTGGAACGAAA 4980  
TTCCTAGAGTTCTTCTAGGAACTAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTT

4981 ACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTT 5040  
TGAGTGCAATTCCTAAAACAGTACTCTAATAGTTTTTCTAGAAAGTGGATCTAGGAAA

5041 TAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACA 5100  
 ATTTAATTTTTACTTCAAATTTAGTTAGATTTTCATATATACTCATTTGAACCAGACTGT  
 ampicillin<sup>R</sup> (5102,5962)  
 |

5101 GTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCA 5160  
 CAATGGTTACGAATTAGTCACTCCGTGGATAGAGTCGCTAGACAGATAAAGCAAGTAGGT

5161 TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCC 5220  
 ATCAACGGACTGAGGGGCAGCACATCTATTGATGCTATGCCCTCCCGAATGGTAGACCGG

5221 CCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAA 5280  
 GGTACACGACGTTACTATGGCGCTCTGGGTGCGAGTGGCCGAGGTCTAAATAGTCGTTATT

5281 ACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCCTCCATCC 5340  
 TGGTCGGTCGGCCTTCCCGGCTCGCGTCTTACCAGGACGTTGAAATAGGCGGAGGTAGG

5341 AGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTTCGCA 5400  
 TCAGATAATTAACAACGGCCCTTCGATCTCATTTCATCAAGCGGTCAATTATCAAACGCGT

5401 ACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCAT 5460  
 TGCAACAACGGTAACGATGTCCGTAGCACCACAGTGCAGCAGCAAACCATAACCGAAGTA

5461 TCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAG 5520  
 AGTCGAGGCCAAGGGTTGCTAGTTCCGCTCAATGTACTAGGGGGTACAACACGTTTTTTTC

5521 CGGTTAGCTCCTTCGGTCCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTTATCAC 5580  
 GCCAATCGAGGAAGCCAGGAGGCTAGCAACAGTCTTCATTCAACCGGCGTCACAATAGTG

5581 TCATGGTTATGGCAGCACTGCATAATTTCTTACTGTCATGCCATCCGTAAGATGCTTTT 5640  
 AGTACCAATACCGTCGTGACGTATTAAGAGAATGACAGTACGGTAGGCATTCTACGAAAA

5641 CTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTT 5700  
 GACACTGACCACTCATGAGTTGGTTCAGTAAGACTCTTATCACATACGCCGCTGGCTCAA

5701 GCTCTTGCCCGCGTCAATACGGGATAAATACCGCGCCACATAGCAGAACTTTAAAAGTGC 5760  
 CGAGAACGGGCCGAGTTATGCCCTATTATGGCGCGGTGTATCGTCTTGAAATTTTCAGC

5761 TCATCATTTGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGAT 5820  
 AGTAGTAACTTTTTGCAAGAAGCCCCGTTTTTGAGAGTTCCTAGAATGGCGACAACCTTA

5821 CCAGTTCGATGTAACCCACTCGTGCACCCAAGTATCTTACGATCTTTTACTTTTACCA 5880  
 GGTCAAGCTACATTGGGTGAGCACGTGGGTGACTAGAAGTCGTAGAAAATGAAAGTGGT

5881 GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGA 5940  
 CGCAAAGACCCACTCGTTTTTTGTCTTCCGTTTTTACGGCGTTTTTTTTCCCTTATTCCCCT

5941 CACGGAAATGTTGAATACTCATACTCTTCCTTTTTTCAATATTATTGAAGCATTATCAGG 6000  
 GTGCCTTTACAACCTTATGAGTATGAGAAGGAAAAAGTTATAATAACTTCGTAAATAGTCC  
 ampicillin promoter (6004,6032)  
 |

6001 GTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAACAAATAGGGG 6060  
 CAATAACAGAGTACTCGCCTATGTATAAACTTACATAAATCTTTTTATTTGTTTATCCCC

6061 TTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC 6098  
AAGGCGCGTGTAAGGGGCTTTTCACGGTGGACTGCAG